Ghent University Academic Bibliography

Show Sort by

Your filters: cql: publisher exact "WILEY-BLACKWELL PUBLISHING, INC"

Add to list
- Journal Article
- A1
Uremic Toxins in Acute Kidney Injury

S Herget-Rosenthal, Griet Glorieux (UGent) , J Jankowski and V Jankowski

(2009) SEMINARS IN DIALYSIS. 22(4). p.445-448
Add to list
- Conference Paper
- C3
INTERSTITIAL FIBROSIS AND FIBROUS INTIMAL THICKENING IN DE NOVO RENAL ALLOGRAFTS UNDER SIROLIMUS OR CYCLOSPORINE: RESULTS OF A RANDOMISED, CONTROLLED TRIAL (FIBRASIC)

AT Woestenburg, Patrick Peeters (UGent) , J Sennesael, D Abramowicz, KM Wissing, C Geers, EA Van Marck, A Van Daele, A Jurgens, B De Winter, et al.

(2009) TRANSPLANT INTERNATIONAL. 22. p.79-79
Add to list
- Conference Paper
- C3
THE IMPACT STUDY: PROPHYLAXIS WITH VALGANCICLOVIR FOR UP TO 200 DAYS POST-TRANSPLANT IN HIGH RISK KIDNEY RECIPIENTS SIGNIFICANTLY REDUCES THE INCIDENCE OF CMV DISEASE COMPARED TO 100 DAYS USE FOLLOWED BY PLACEBO

AG Jardine, Y Lebranchu, F Vincenti, I Hauser, E Blumberg, J Punch, D Abramowicz, J Ives, Patrick Peeters (UGent) , N Pluck, et al.

(2009) TRANSPLANT INTERNATIONAL. 22. p.93-93
Add to list
- Conference Paper
- C3
The IMPACT Study: Valganciclovir Prophylaxis for until 200 Days Post-Transplant in High Risk Kidney Recipients Substantially Reduces the Incidence of CMV Disease.

A Humar, Y Lebranchu, F Vincenti, J Punch, D Abramowicz, E Blumberg, I Hauser, A Limaye, J Ives, N Pluck, et al.

(2009) AMERICAN JOURNAL OF TRANSPLANTATION. 9. p.248-249
Add to list
- Conference Paper
- C3
MELD ALLOCATION SYSTEM IN BELGIUM-ET AND OUTCOME

MAURICIO SAINZ-BARRIGA (UGent) , Ivo Haentjens (UGent) , EVA-LINE DECOSTER (UGent) , Luc Colenbie (UGent) , BERT VAN DEN BOSSCHE (UGent) , Frederik Berrevoet (UGent) , Anja Geerts (UGent) , Isabelle Colle (UGent) , Hans Van Vlierberghe (UGent) , Xavier Rogiers (UGent) , et al.

(2009) TRANSPLANT INTERNATIONAL. 22. p.108-109
Add to list
- Conference Paper
- C3
LIVER TRANSPLANTATION (LT) FROM DONATION AFTER CARDIAC DEATH (DCD) DONORS: MULTICENTRE BELGIAN EXPERIENCE 2003-2007

O Detry, V Donckier, V Lucidi, D Ysebaert, T Chapelle, J Lerut, O Ciccarelli, J Pirenne, D Monbaliu, A Deroover, et al.

(2009) TRANSPLANT INTERNATIONAL. 22. p.62-62
Add to list
'I need help on Mondays. The other days I'm ok.' Perspectives of disabled children on inclusive education

Elisabeth De Schauwer (UGent) , Geert Van Hove (UGent) , Kathleen Mortier (UGent) and Gerrit Loots (UGent)

(2009) CHILDREN & SOCIETY. 23(2). p.99-111
Add to list
- Journal Article
- A1
Estimation of controlled direct effects

Sylvie Goetgeluk, Stijn Vansteelandt (UGent) and Els Goetghebeur (UGent)

(2008) JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES B-STATISTICAL METHODOLOGY. 70(5). p.1049-4066
Add to list
- Conference Paper
- C3
Complement factor B deficiency associated with recurrent asceptic meningitis

Filomeen Haerynck (UGent) , Petra Schelstraete (UGent) , Johan Vande Walle (UGent) , Rudy Van Coster (UGent) , Maria Bordon Cueto De Braem (UGent) , F Mascart and Jo Dehoorne (UGent)

(2008) CLINICAL AND EXPERIMENTAL IMMUNOLOGY. 154(1). p.4-5

← Previous

Academic Bibliography

Uremic Toxins in Acute Kidney Injury

INTERSTITIAL FIBROSIS AND FIBROUS INTIMAL THICKENING IN DE NOVO RENAL ALLOGRAFTS UNDER SIROLIMUS OR CYCLOSPORINE: RESULTS OF A RANDOMISED, CONTROLLED TRIAL (FIBRASIC)

THE IMPACT STUDY: PROPHYLAXIS WITH VALGANCICLOVIR FOR UP TO 200 DAYS POST-TRANSPLANT IN HIGH RISK KIDNEY RECIPIENTS SIGNIFICANTLY REDUCES THE INCIDENCE OF CMV DISEASE COMPARED TO 100 DAYS USE FOLLOWED BY PLACEBO

The IMPACT Study: Valganciclovir Prophylaxis for until 200 Days Post-Transplant in High Risk Kidney Recipients Substantially Reduces the Incidence of CMV Disease.

MELD ALLOCATION SYSTEM IN BELGIUM-ET AND OUTCOME

LIVER TRANSPLANTATION (LT) FROM DONATION AFTER CARDIAC DEATH (DCD) DONORS: MULTICENTRE BELGIAN EXPERIENCE 2003-2007

'I need help on Mondays. The other days I'm ok.' Perspectives of disabled children on inclusive education

Estimation of controlled direct effects

Complement factor B deficiency associated with recurrent asceptic meningitis

Contents

Support

Contact